Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gastrointestinal tract luminal water content refers to the amount of free water within the lumen of the GI tract, regulated by ingestion, secretion, and absorption processes across the intestinal epithelium[1][3][4]. It is a dynamic parameter influencing oral drug absorption (especially for poorly soluble drugs), digestion, and mucosal health[1][4]. Water content is affected by factors such as fluid intake, dietary composition, transporter and channel activity (e.g., NHE3, aquaporins)[3][1], and GI disease states. While not a molecular drug target, luminal water content is manipulated pharmacologically (e.g., with osmotic agents/laxatives) and is crucial for modeling GI physiology, drug pharmacokinetics, and the management of certain GI disorders[1][3][4].
Drugs modulating this parameter typically do so by altering water absorption/secretion via ion transporters (e.g., NHE3 inhibition), changing GI lumen osmotic pressure (e.g., osmotic laxatives draw water into lumen), or enhancing water retention/promoting secretion across epithelial cells.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastrointestinal tract luminal water content.